pHion Therapeutics is a UK based vaccine development company, developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and DNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo, irrespective of size into nanoparticles, which are highly efficient at cellular entry. The platform has the added advantage of ease of scalability and logistics, including stability at room temperature.

OUR VISION
To develop advanced therapeutics for global patient benefit in cancer and infectious diseases
OUR MISSION
To develop next generation vaccines through stealth-like delivery of mRNA
LATEST NEWS
22 June 2023
pHion Therapeutics and Queen’s announce £1million funding for a new vaccine for prostate cancer
LATEST PUBLICATION
3 November 2022
Delivery of a peptide/microRNA blend via electrospun antimicrobial nanofibres for wound repair

Bombin ADJ, Dunne N, McCarthy HO.